Saltar al contenido
Merck

Saltar a

C6352

CTAP

≥95%

Iniciar sesión para ver los precios por organización y contrato.

Seleccione un Tamaño

Cambiar Vistas
Tamaño de envaseSKUDisponibilidadPrecio
1 mg
Comprobar disponibilidad del carrito
US$ 297,00

Acerca de este artículo

Fórmula empírica (notación de Hill):
C51H69N13O11S2
Número CAS:
Peso molecular:
1104.30
NACRES:
NA.32
PubChem Substance ID:
UNSPSC Code:
12352200
MDL number:

US$ 297,00

PRECIOS SIN IMPUESTOS NACIONALES

Comprobar disponibilidad del carrito

Solicite una orden a granel
Servicio técnico
¿Necesita ayuda? Nuestro equipo de científicos experimentados está aquí para ayudarle.
Permítanos ayudarle


Quality Level

assay

≥95%

form

powder

UniProt accession no.

storage temp.

−20°C

SMILES string

C[C@@H](O)[C@H](NC(=O)[C@H]1NC(=O)[C@@H](NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](Cc2c[nH]c3ccccc23)NC(=O)[C@H](Cc4ccc(O)cc4)NC(=O)[C@H](CSSC1(C)C)NC(=O)[C@H](N)Cc5ccccc5)[C@@H](C)O)C(N)=O

InChI

1S/C51H69N13O11S2/c1-26(65)39(42(53)68)62-49(75)41-51(3,4)77-76-25-38(61-43(69)33(52)21-28-11-6-5-7-12-28)47(73)59-36(22-29-16-18-31(67)19-17-29)45(71)60-37(23-30-24-57-34-14-9-8-13-32(30)34)46(72)58-35(15-10-20-56-50(54)55)44(70)63-40(27(2)66)48(74)64-41/h5-9,11-14,16-19,24,26-27,33,35-41,57,65-67H,10,15,20-23,25,52H2,1-4H3,(H2,53,68)(H,58,72)(H,59,73)(H,60,71)(H,61,69)(H,62,75)(H,63,70)(H,64,74)(H4,54,55,56)/t26-,27-,33-,35+,36+,37-,38+,39+,40+,41-/m1/s1

InChI key

OFMQLVRLOGHAJI-FGHAYEPSSA-N

Gene Information

rat ... Pnoc(25516)

Application

CTAP has been used as a μ-opioid receptor (MOR) antagonist:
  • to study the anti-hyperalgesic effect of dipeptidyl peptidase 4 (DPP4) inhibitor isoleucine-proline-isoleucine (IPI) and vildagliptin in carrageenan-induced inflammation
  • to study the role of MOR in glutamate and gamma-aminobutyric acid (GABA) efflux during predator stress in rats[1]
  • to determine the endogenous opioid peptide involved in blocking pain induced by activated gastrin-releasing peptide (Grp+) neurons

Biochem/physiol Actions

CTAP is a peptide antagonist produced from somatostatin analogs.

Comparar elementos similares

Ver comparación completa

Mostrar Diferencias

1 of 1

Este artículo
P5296EMU087231EMU020531
assay

≥95%

assay

≥97% (HPLC)

assay

-

assay

-

Quality Level

200

Quality Level

100

Quality Level

100

Quality Level

100

form

powder

form

powder

form

lyophilized powder

form

lyophilized powder

storage temp.

−20°C

storage temp.

−20°C

storage temp.

−20°C

storage temp.

−20°C

UniProt accession no.

Q62923

UniProt accession no.

Q64387

UniProt accession no.

-

UniProt accession no.

-

Gene Information

rat ... Pnoc(25516)

Gene Information

mouse ... Pnoc(18155)

Gene Information

mouse ... PNO1(66249), Pno1(66249)

Gene Information

mouse ... SLC20A2(20516), Slc20a2(20516)


Still not finding the right product?

Explore all of our products under


Clase de almacenamiento

11 - Combustible Solids

wgk

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable

ppe

Eyeshields, Gloves, type N95 (US)



Elija entre una de las versiones más recientes:

Certificados de análisis (COA)

Lot/Batch Number

¿No ve la versión correcta?

Si necesita una versión concreta, puede buscar un certificado específico por el número de lote.

¿Ya tiene este producto?

Encuentre la documentación para los productos que ha comprado recientemente en la Biblioteca de documentos.

Visite la Librería de documentos



E J Bilsky et al.
The Journal of pharmacology and experimental therapeutics, 277(1), 484-490 (1996-04-01)
Previous studies measuring opioid inhibition of cyclic adenosine monophosphate in SH-SY5Y cells supported the hypothesis that continuous agonist stimulation causes a gradual conversion of the mu opioid receptor to a sensitized or constitutively active state termed mu*. Conversion to mu*
Pathology and glia type specific changes of the DPP4 activity in the spinal cord contributes to the development and maintenance of hyperalgesia and shapes opioid signalling in chronic pain states
Kiraly K, et al.
Scientific Reports (2017)
Christine E Engeland et al.
Virology, 460-461, 194-206 (2014-07-11)
Human immunodeficiency virus Gag drives assembly of virions in infected cells and interacts with host factors which facilitate or restrict viral replication. Although several Gag-binding proteins have been characterized, understanding of virus-host interactions remains incomplete. In a series of six



Número de artículo de comercio global

SKUGTIN
C6352-1MG04061826152607

Questions

Reviews

No rating value

Active Filters